` P6NA (Acer Therapeutics Inc) vs DAX Index Comparison - Alpha Spread

A
P6NA
vs
D
DAX Index

Over the past 12 months, P6NA has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +19% growth.

Stocks Performance
P6NA vs DAX Index

Loading
P6NA
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
P6NA vs DAX Index

Performance Gap Between P6NA and GDAXI
HIDDEN
Show

Performance By Year
P6NA vs DAX Index

Loading
P6NA
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Acer Therapeutics Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Acer Therapeutics Inc
Glance View

Market Cap
28.8m EUR
Industry
Pharmaceuticals

Acer Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2006-09-01. The Company’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate), ACER-801 (osanetant), EDSIVO (celiprolol) and ACER-2820 (emetine). ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.

P6NA Intrinsic Value
Not Available
Back to Top